@ModeXTx profile picture
ModeX Therapeutics @ModeXTx

We are shaping a new and better way to make transformational medicines a reality for people in need. ModeX is an OPKO Health company (Nasdaq: OPK).

Joined November 2022
  • Tweets 74
  • Following 117
  • Followers 75
61 Photos and videos
ModeX’s Dr. John Mascola will be at World Vaccine Congress 2026 to discuss the development of unique tetravalent antibodies for COVID and influenza highlighting ModeX’s work in this area. If you are at the Congress, drop in and join the conversation. @jrmascola
1
4
83
We are excited to announce we have initiated Phase 1/2a clinical trial (NCT07110584) with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology and immune disorders. See here for more bit.ly/436FmEW $OPK #multispecifics #antibodies

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster

modextherapeutics.com
2
139
Don’t miss ModeX Therapeutics’s poster presentation at #ESMO25 and stay at the forefront of research with multispecific antibodies. Learn more about our pipeline here: bit.ly/42LYd80
1
91
ModeX Therapeutics retweeted
BiotechTV
@BiotechTV
29 Jul 2025
𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰 𝐍𝐢𝐠𝐡𝐭: From Boston, former NIH Director Elias Zerhouni will discuss with BiotechTV the current political and policy environment, and how it is affecting science.
2
7
3,847
Join Us: Jefferies Global Healthcare Conference: OPKO Health, Inc. (OPK): opko.com/investors/news-even…
1
3
144
Excited to share that Dr. Ronnie Wei, Head of Biologics Discovery and Development, appeared on the @Lonza Podcast to answer questions on what antibodies are, how they are made, and why development in this space has accelerated rapidly. Listen here: bit.ly/41mZsul $OPK
1
3
270
#ICYMI Modex was thrilled to be presenting preclinical data on MDX2001, a tetraspecific for targeting solid tumor malignancies today at #SITC24 Details found here: bit.ly/40r06qj $OPK
2
2
448
ModeX is excited to share information about MDX2001, a novel tetraspecific T cell engager for treatment of advanced solid tumors, at #SITC24 on Nov. 8. Stop by our posters in the Exhibit Hall to learn more. Details found here: bit.ly/40r06qj Tags: $OPK
2
4
372
Want to know more about what we do? Check out our latest publication in Science Translational Medicine, where we show the potential of multispecific antibodies against #COVID-19. Read more here: science.org/doi/10.1126/scit…

A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylac...

Multispecific antibodies to SARS-CoV-2 increase pseudovirus neutralization breadth and potency and inhibit immune escape in vitro.

science.org
2
1
84
ModeX Therapeutics retweeted
BioCentury@BioCentury
24 Sep 2024
On the latest #BioCenturyThisWeek podcast: Pediatric PRVs, Biosecure in Congress & @NovoNordisk’s #obesity miss, with @SteveUsdin1 @StephenPHansen @Jeff_Cranmer buff.ly/4efWVpm
3
2
868
Happy International Women's Day! Today we celebrate each of the incredible women at ModeX for their commitment to advancing science and creating new medicines. We're grateful to be able to empower each other on our path to making a difference for patients together. #IWD24
1
290
Today we announced results from a Phase 1 clinical study of SAR441236, a trispecific antibody for the treatment and prevention of #HIV, at the 2024 Conference on Retroviruses and Opportunistic Infections (#CROI). Learn more: bit.ly/4c2Jzw3
1
737
On #EmployeeAppreciationDay we thank the ModeX team who embody our commitment to creating innovative medicines with their drive for scientific excellence, mission-oriented focus and collaborative spirit. We’re endlessly proud of all the work that you do! #biotechjobs #MakingModeX
0:20
1
140
At ModeX Alicia integrates the team's many skills to progress our goal of developing transformative #multispecific medicines. Managing projects on the oncology team, she treats every day as an opportunity to advance our pipeline. More on us: bit.ly/47Pb0GT #biotechjobs
1
89
By combining multiple antigen-binding sites into a single molecule, our multispecific antibodies are as space-efficient as they can be. Our MSTAR platform simplifies gene expression, allowing for more efficient manufacturing & gene-based antibody delivery. bit.ly/3FOQRoe
0:08
3
4
120
Did you know that the HIV virus is one of the most genetically diverse pathogens? Our multispecific HIV antibody, derived from our MSTAR platform, has the potential to potently target more HIV strains than any monospecific antibody. Learn more: bit.ly/3FOQRoe
0:23
2
2
136
One of the first people ModeX employees meet is our Head of HR Lana DeAngelis who is passionate about empowering all members of our team to meaningfully contribute to our shared mission. Learn more about what sets ModeX apart: bit.ly/47Pb0GT #Biotechjobs
1
70
We're creating next generation therapies by uniting the power of multiple medicines into a single molecule. In #cancer, our multispecifics can expand the number of targeted tumor antigens and enable better immune system activation. bit.ly/3FOQRoe #WorldCancerDay
1
74
Our President and CEO Gary Nabel spoke at @NIH's Industry Day to discuss how public and private sectors can work together towards a shared goal of saving lives, like our partnership with @BARDA to leverage our multispecific antibody platform MSTAR to combat infectious disease.
1
3
89
Our President and CEO Gary Nabel will give the plenary address at @NIH's Industry Day this Thursday, January 18. He will focus on the industry perspective on NIH research being done to target unmet needs across the U.S. Learn more: bit.ly/48X773k
73
Load more